Edwin Kuffner M.D.

CDC Director Mandy Cohen has endorsed important new recommendations from the Advisory Committee on Immunization Practices (ACIP) to help protect against serious illnesses. For those 65+ and individuals who are moderately or severely immunocompromised, a second dose of the 2024-2025 COVID-19 vaccine is recommended six months after the first dose. This guidance reflects the latest data on vaccine effectiveness and the ongoing circulation of COVID-19. Receiving this additional dose boosts protection against the virus variants driving infections and hospitalizations, while also reducing the risk of Long COVID, which can have lasting effects. Additionally, the ACIP has lowered the recommended age for pneumococcal vaccination from 65 to 50. This change allows more adults to protect themselves against pneumococcal disease, which can lead to pneumonia, meningitis, and bloodstream infections. Adults 50 and older should talk to their healthcare provider to ensure they're up to date on pneumococcal vaccination, especially as we approach the winter respiratory season. #CDC #COVIDVACCINE #PNEUMOCOCCALVACCINE #ACIP

9

Managing treatment failure is a multistep process requiring complex coordination and accountability, but the New Horizons Collaborative is addressing this head on. Read our latest brief on building health system capacity. https://lnkd.in/eu5vPi2s

37

1 Comment

Discover if you're at risk for kidney disease—1 in 3 American adults may be. Take The Rogosin Institute's quiz now to see if you’re at risk: rogosin.org/risk-survey

2

CDC issues Health Alert Network (HAN) Health Advisory to notify healthcare providers, public health authorities and the public of an increased risk of dengue virus (DENV) infections in U.S. in 2024 Providers should: 1) Have increased suspicion of dengue among people with fever who have been in areas with frequent or continuous dengue transmission within 14 days before illness onset 2) Order appropriate diagnostic tests for acute DENV infection. 3) Ensure timely reporting of dengue cases to public health authorities. 4) Promote mosquito bite prevention measures among people living in or visiting areas with frequent or continuous dengue transmission. Read full advisory: https://bit.ly/3ziWbjM

428

5 Comments

In this exciting clip, watch Andrew M. Evens, DO, MBA, MSc Deputy Director for Clinical Services at Rutgers Cancer Institute and System Director of Medical Oncology and Oncology Lead at RWJBarnabas Health be interviewed by Dr. Matthew Matasar, Chief of the Division of Blood Disorders at Rutgers Cancer Institute. Learn about the new Jack and Sheryl Morris Cancer Center, Dr. Evens work in Hodgkin Lymphoma, and the exciting research happening at #ASH24! American Society of Hematology

14

📣 Just released: The Access Accelerated in Action 2023 Measurement and Evaluation report reviews key accomplishments of the Access Accelerated – The World Bank in 2023: ✅ stronger policy evidence ✅ improved patient care ✅ an additional US$360M secured for future #NCD prevention & care efforts. Discover how our collaboration is supporting governments across four continents and making a difference: https://lnkd.in/ez-Vzasc

13

2 Comments

The American College of Cardiology (ACC) recently published a report card on the excess cardiovascular mortality among Black Americans between 2000-2022. The report highlights the urgent need for more research into health policies, social determinants, and structural factors, calling for solutions to eliminate persistent health inequities. At Acarix, we understand risk stratification of patients with stable chest pain can be challenging, especially in care settings with limited cardiology resources, lack of access to diagnostic testing, or high patient volumes that result in extended wait times for assessment. The CADScor System offers physicians an advanced acoustic-based diagnostic aid to easily and quickly rule out significant coronary artery disease, designed to maximize accessibility for all patients with clear results at point of care. #Acarix #CADScorSystem #coronaryarterydisease #CAD #healthequity #cardiology #ED #emergencydepartment #primarycare #pointofcare

24

AAPath ADVOCACY ACTIONS UPDATE (1 of 2) From the desk of AAPath’s Deputy Director, Lydia P. Howell, MD AAPath continues to oppose the FDA’s recent rule to regulate laboratory-developed tests like medical devices. Here’s what’s been happening with the LDT issue in September: There is ongoing interest in Congress in bringing back the proposed VALID Act (Verifying Accurate Leading-edge IVCT Development Act, https://lnkd.in/ezvw8jbU). Proposed in 2023 by Representative Bushon (R-IN), the intent behind this legislation was to create an FDA regulatory framework specific to diagnostics; however, it has not yet been passed in Congress. AAPath has been opposed to the VALID Act on the principle that the FDA does not have formal authority to regulate tests and because the onerous requirements will stop test innovation and harm patients. Many other stakeholders, however, are hoping that the VALID Act now gains traction, since it may appear more appealing than the proposed FDA rule. Draft modifications to VALID are circulating from Representative Bushon and colleague Representative Diana DeGette (D-CO). Highlights of these modifications include: - The provision of two options for defining high-risk tests, both involving risk for irreversible harm. - A humanitarian exemption on tests with volumes less than 10,000 annually. - A low-volume and custom test exemption for tests with volumes of 5-10 tests annually. - An exemption for tests approved by the New York State Clinical Lab Evaluation Program (CLEP) would be from the PMA requirement. Most problematic are the following two modifications, which several organizations are seeking to address: - For LDTs offered because of unmet need, pre-market approval (PMA) will not be required until the test is on the test menu for 180 days (180 days is deemed too short). - Tests using high-risk new technologies should be offered under a new Technology Certificate Program (this new certificate program is unfamiliar and uncertain). The College of American Pathologists gathered several organizations (AAPath, AMP, ASCP, ASC) together in mid-September to discuss where the organizations might find common ground to postpone the rule, and move forward in a mutually agreeable way for LDT regulation. Highlights of the discussion included: - Lack of common interest in supporting the VALID Act; most did not support bringing back VALID. - Strategies shared to oppose the proposed rule included: - Finding patient stories to share with outside stakeholders; - Networking with large patient organizations; - Supporting a recent survey by the Association for Molecular Pathology (AMP); and - Postponing implementation of the final rule.

1

The NIH has announced a new NOFO: “Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional)” (RFA-RM-24-010). https://go.nih.gov/gz5JDK6

1

The NIH has announced a new NOFO: “Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional)” (RFA-RM-24-010). https://go.nih.gov/gz5JDK6

1

Join us for a free UCB-sponsored webinar on Wednesday, April 24, 2024, with Wendy Cantrell, DNP, CRNP, Kara Gooding, MMS, PA-C, Joe Gorelick, MSN, FNP-C, and Andrea Nguyen, PA-C, MPAS. - Get NP/PA perspectives and real-world insights as panelists present and discuss their own patient cases managed with IL-17 inhibitors. - Learn about the science of IL-17 inhibition and key therapeutic considerations for this growing class of biologic agents. - Explore the latest data on treatment outcomes with a focus on patient and prescriber expectations of “treatment success.” - Discover key considerations related to patient selection and screening, as well as treatment initiation and monitoring. Register for FREE: https://lnkd.in/eyckBZUu

14

What are the health disparity populations covered in #HDPulse? Visit HDPulse to access minority health and #HealthDisparities data and interventions about your population of interest: https://bit.ly/3XmLd6A

64

1 Comment

Check out #HDPulse! A new ecosystem of #healthdisparities and #minorityhealth resources from National Institute on Minority Health and Health Disparities (NIMHD)

3